Cargando…
ICER, ISPOR AND QALYs: Tales of Imaginary Worlds
Previous commentaries in the Formulary Evaluation section of INNOVATIONS in Pharmacy have pointed to the lack of credibility in modeled claims for cost-effectiveness and associated recommendations for pricing by the Institute for Clinical and Economic Review (ICER). The principal objection to ICER r...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
University of Minnesota Libraries Publishing
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051886/ https://www.ncbi.nlm.nih.gov/pubmed/34007578 http://dx.doi.org/10.24926/iip.v10i4.2266 |